0RA9
vs
D
DAX Index
0RA9
Over the past 12 months, 0RA9 has significantly outperformed DAX Index, delivering a return of +1 654% compared to the DAX Index's +14% growth.
Stocks Performance
0RA9 vs DAX Index
Performance Gap
0RA9 vs DAX Index
Performance By Year
0RA9 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.